Currency and Market Risks - The company is exposed to fluctuations in currency exchange rates, which could negatively affect operating results, particularly if the U.S. dollar strengthens, increasing costs for international customers [167]. - A significant portion of operating revenues and expenses is incurred outside the U.S., making them subject to foreign currency fluctuations, which could adversely affect financial performance [167]. - The company has not engaged in hedging foreign currency transactions, increasing vulnerability to adverse financial impacts from currency fluctuations [168]. - A strengthening or weakening of the U.S. dollar against other currencies may negatively or positively affect the company's operating results [340]. - The company is exposed to market risks primarily due to fluctuations in foreign currency exchange and interest rates [337]. Legal and Regulatory Risks - Legal and regulatory risks related to data protection and privacy laws could result in substantial costs and liabilities, potentially impacting sales of software [173]. - The company is subject to various laws and regulations, including the GDPR, which imposes strict obligations on data protection and could lead to fines up to €20 million or 4% of global turnover for non-compliance [175]. - Ongoing legal proceedings and litigation could result in significant liabilities and increased costs, potentially diverting resources from core business activities [178]. - Compliance with evolving privacy and data protection laws may require changes to business practices, potentially increasing operational costs [175]. - Future legal developments regarding data transfer regulations may require modifications to operational practices, potentially incurring greater costs [177]. - Compliance with legal and regulatory requirements in various countries is crucial; failure to meet these could result in significant liabilities and loss of customers [188]. - Non-compliance with anti-corruption and anti-bribery laws could result in significant legal liabilities and harm the company's business [205]. - The use of open source software may expose the company to litigation risks and could require costly changes to proprietary products [189]. - Indemnity provisions in customer agreements could lead to substantial liabilities for intellectual property infringement and data protection violations [190]. - The company is subject to potential securities class action litigation, which could result in substantial costs and divert management's attention [208]. Intellectual Property Risks - The company relies on a combination of patents and other intellectual property protections, but there is no guarantee that these will provide competitive advantages or be upheld in litigation [183]. - The company may face challenges in protecting proprietary technology, which could impair competitive position and lead to reduced revenue [183]. - The inability to enforce intellectual property rights could lead to delays in product sales and impair functionality, negatively impacting the company's reputation [187]. - The company may incur significant costs to monitor and protect its intellectual property rights, including potential litigation expenses [185]. Financial Position and Operations - Changes in tax laws and interpretations may adversely affect the company's financial position and results of operations [192]. - The company may face increased scrutiny and potential penalties related to its tax positions and transfer pricing in various jurisdictions [193]. - The implementation of new critical systems may disrupt operations and affect internal reporting processes [200]. - The company had cash, cash equivalents, restricted cash, and investments totaling $1.1 billion as of January 31, 2026 [338]. - A hypothetical 100 basis point increase in interest rates would result in an approximate $2.7 million decrease in the fair value of the investment portfolio [338]. - The company has a secured revolving credit facility of $750.0 million, which may be increased by an additional $250.0 million [339]. Operational Risks - Unfavorable conditions in the global economy could limit the company's ability to grow and negatively affect operating results [216]. - The company may experience disruptions due to natural catastrophic events and man-made problems, impacting business operations [217]. - Anti-takeover provisions in the company's charter documents could make acquisitions more difficult and limit stockholder actions [209].

Revenue Concentration - TAT's revenues from five major customers accounted for approximately 32.6%, 29.9%, and 28.46% for the years ended December 31, 2025, 2024, and 2023, respectively [56]. - Sales to the U.S. and Israeli governments represented approximately 9.3%, 12.4%, and 8.3% of TAT's revenues for the years ended December 31, 2025, 2024, and 2023, respectively [57]. - TAT's international sales accounted for approximately 92%, 94%, and 93% of total sales for the years ended December 31, 2025, 2024, and 2023, respectively, indicating a high revenue concentration from international markets [70]. - Direct sales to the U.S. government accounted for approximately 7.7% of TAT's revenues for the year ended December 31, 2025, compared to 9.3% in 2024 and 6.6% in 2023 [189]. Supplier and Inventory Risks - TAT relies on a limited number of key suppliers, with Honeywell International Inc. being a significant supplier for APU spare parts and other components [62]. - The company is exposed to risks related to inventory management, which could lead to supply imbalances [43]. - TAT's inventory management poses significant risks, as failure to effectively manage inventory levels could lead to supply imbalances and adversely affect business operations [68]. - TAT relies on a limited number of suppliers for components, which could impact manufacturing timelines if delays occur [221]. Competition and Market Position - TAT faces competition from established companies with greater resources, which may impact its market position and financial health [48]. - TAT's competitive environment in the aerospace and defense OEM industries is characterized by intense competition, with a focus on technological innovations, price, quality, and on-time delivery [197]. - TAT's major competitors in the MRO services market include AAR Corp, Honeywell, and Lufthansa Technik, which have inherent competitive advantages such as better name recognition and access to superior technology [200]. Financial and Operational Risks - TAT's backlog of projects is subject to unexpected adjustments, delays in payments, and cancellations, which could affect financial results [43]. - The company may engage in future acquisitions that could dilute shareholders' equity and impact business operations [43]. - TAT's operations may be adversely affected by changes in government trade policies and international trade disputes [65]. - TAT may face increased labor and raw materials costs, which could adversely affect operating profits and margins, particularly if inflationary pressures persist [66]. - TAT's financial statements are affected by fluctuations in the exchange rate between the NIS and the U.S. dollar, which can impact profitability and period-to-period comparisons [90]. - TAT's operations may be adversely affected by military service obligations of its personnel, with many employees currently serving in the IDF due to ongoing conflicts [103]. - The current war and hostilities in Israel have made it difficult to predict the economic implications on TAT's business and operations [99]. - TAT is restricted from marketing its products to certain countries, which may adversely impact operations and financial results [100]. - The Israeli government's proposed judicial reforms could potentially affect the macroeconomic conditions in which TAT operates [101]. - TAT's share price may be depressed due to Israeli corporate law regulations that complicate acquisitions and changes of control [105]. - The company has a history of volatility in its share price, which may lead to potential securities litigation in the future [93]. - TAT's registered offices are located in Israel, and its operations are subject to local political and economic conditions that could materially affect business [95]. Strategic Initiatives and R&D - TAT's future success depends on its ability to develop new offerings and technologies [41]. - TAT aims to enhance its OEM capabilities by expanding offerings to new aircraft platforms, including electrification and eVTOL [154]. - TAT established a new R&D lab, FutureWorks, in Charlotte, North Carolina, to develop next-generation thermal management systems for eVTOL aircraft, addressing challenges in cooling performance, weight reduction, and compact design [215]. - The R&D lab features advanced testing and simulation infrastructure, focusing on performance optimization, reliability, and durability of thermal management systems [216]. - TAT's strategic vision emphasizes collaboration with customers and industry stakeholders to co-develop tailored solutions that meet specific operational and environmental constraints [217]. - The company aims to exceed customer expectations by delivering future-ready thermal management systems that set new industry benchmarks [220]. Subsidiaries and Services - Limco, a subsidiary of TAT, provides MRO services for heat transfer components and is certified by FAA, EASA, and the Civil Aviation Administration of China [137]. - Turbochrome, another subsidiary, specializes in MRO services for jet engine components and provides coating powders and masking materials to OEMs [148]. - TAT's subsidiaries operate FAA- and EASA-certified repair stations, ensuring compliance with industry standards for MRO services [142]. - TAT's MRO contracts with customers are generally long-term engagements, with terms ranging from one to ten years or more [144]. - Piedmont provides MRO services for APUs and landing gear, with a focus on comprehensive repair and overhaul services for Honeywell APU models [177]. - Turbochrome plans to expand its MRO operations by developing capabilities for additional types of jet engine components with significant commercial potential [182]. Compliance and Regulatory Environment - The aerospace industry is highly regulated, and TAT may incur significant fines and penalties if it fails to comply with regulations [47]. - TAT's operations are subject to various environmental laws and regulations, and non-compliance could result in significant liabilities and operational limitations [83]. - The company is subject to extensive aerospace regulations and believes it meets or exceeds FAA maintenance standards in its repair and overhaul activities [230][231]. - TAT's operations in Israel are certified by the Israeli Ministry of Defense and the Civil Aviation Administration, requiring export permits for certain products [234]. Engineering and Innovation - TAT's engineering capabilities are a strategic core competency, enabling the company to meet complex customer demands while maintaining efficient development cycles [209]. - TAT is focused on enhancing its engineering capabilities and investing in new technologies to strengthen its market position and enter more advanced platforms [208]. - TAT estimates the market size for Turbochrome's MRO services to be significant, based on the number of jet engines requiring these services [182]. - The demand for MRO services is driven by the aging aircraft fleet and increased maintenance costs, leading carriers to seek reliable third-party providers [164][175].

Clinical Trials and Development - Annamycin is currently in a pivotal Phase 3 trial (MIRACLE trial) for relapsed/refractory acute myeloid leukemia (AML), with interim unblinding expected in mid-2026[21]. - The company has completed a total of eighteen clinical trials across its three core portfolios, with ongoing and planned trials for Annamycin and other drug candidates[22][32]. - The MIRACLE trial has shown promising blinded safety and efficacy data for the first 30 subjects treated, with further data expected for the first 45 subjects[25]. - The company is planning a Phase 1B/2 trial for Annamycin as a monotherapy for third-line pancreatic cancer, expected to begin in 2026[32]. - The Phase 1B/2 trial for Annamycin in STS lung metastases (MB-107) reported a median overall survival (OS) of 13.5 months[1]. - The Phase 1 clinical trial for pediatric brain tumors with WP1066 concluded with positive results, including partial tumor response in a DIPG patient[46]. - The MB-106 trial included 23 subjects recruited on an Intent-To-Treat (ITT) basis, with 22 subjects safety evaluable[39]. - The interim unblinding of the MIRACLE trial is expected to occur in mid-2026, with the first 45 subjects treated[43]. - The amended protocol allows for an interim unblinding of data for the first 45 subjects treated across three arms of the trial[43]. - The final clinical study report (CSR) for the MB-106 trial is expected to be published in late March 2026[90]. - The FDA approved the design of a Phase 2B/3 pivotal trial for AML patients who are refractory or relapsed after induction therapy, with a focus on complete remission as the primary endpoint[92]. - The MIRACLE trial will include 222 subjects in Part B, randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin[100]. - The preliminary composite complete remission rate in the MIRACLE trial's first 30 subjects was reported at 40%, outperforming historical outcomes for cytarabine alone[98]. - The Phase 1B portion of the MB-106 trial has successfully completed recruitment, with a focus on both first-line and second-line therapy subjects[89]. Drug Efficacy and Safety - Annamycin has demonstrated a complete remission (CR) rate of 50% and a composite CR rate of 60% in combination with Cytarabine for R/R AML as second-line therapy[25]. - Annamycin is designed to be non-cardiotoxic, with some patients safely dosed at five times the typical lifetime maximum allowable anthracycline dose[25]. - The FDA's feedback indicated no cardiotoxicity in previous trials, supporting the continuation of Annamycin's clinical development[40]. - Clinical trials have shown no evidence of cardiotoxicity in over 100 subjects treated with Annamycin, including 90 subjects across five trials, with one subject receiving a cumulative dose of 3420 mg/m2 without cardiotoxic effects[59]. - Annamycin has shown a 100% survival rate in a preclinical study for metastatic osteosarcoma, compared to only 10% for untreated animals, indicating its potential therapeutic benefits[68]. - Annamycin has shown no signs of drug-related cardiotoxicity, allowing for higher dosing and potential treatment of traditionally "Unfit" patients[75]. - In the MB-106 trial, 36% of all subjects achieved a complete response (CR), with a median overall survival (OS) of 15.2 months for CR responders[86]. - Annamycin's unique multilamellar lipid-based delivery system is designed to improve bioavailability and increase the therapeutic window[24]. - Annamycin's unique multilamellar lipid delivery mechanism enhances its pharmacokinetics, resulting in improved tissue distribution and retention compared to existing anthracyclines[51]. - The drug demonstrates a significant ability to overcome multidrug resistance, potentially allowing for higher drug uptake in diseased cells and more effective treatment outcomes[61]. Market and Competitive Landscape - Approximately 150,000 people are living with AML worldwide, with over 20,000 new diagnoses annually in the U.S.[69]. - An estimated 60% of AML patients have a significant unmet need for new therapies, as only about 40% can achieve a curative bone marrow transplant or lasting remission[69]. - The 5-year survival rate for AML is roughly 30%[69]. - Only about 36% of "Fit" patients achieve a durable complete response (CR) from the standard "7+3" therapy, translating to approximately 14% of all AML patients[71]. - For "Unfit" patients treated with "Ven-Aza," the success rate is around 37%, leading to about 15% of all AML patients achieving a positive outcome[72]. - Six new targeted therapies have been approved for 2nd line patients, but only about 21% of these patients achieve a durable CR, affecting an additional 18% of the AML population[74]. - The global market for anthracyclines, including the lead drug candidate Annamycin, was estimated at $1.3 billion in 2023 and is projected to grow to $2 billion by 2032[176]. - The market for soft tissue sarcoma (STS) is estimated to be $1.58 billion in 2024, with expectations to grow to $2.57 billion by 2030[180]. - An estimated 67,440 new cases of pancreatic cancer will be diagnosed in the US in 2025, with a mortality rate of 51,980[182]. - The oncology drug market has seen checkpoint inhibitors generate over $10 billion in annual revenues, but they are ineffective in certain "non-responsive" tumors, prompting a focus on combination therapies[114][115]. Regulatory and Developmental Designations - The company has obtained patent protection for Annamycin through 2040, with potential extensions to 2045, along with Orphan Drug and Fast Track designations[27]. - Annamycin has received Orphan Drug Designation from the FDA and EMA for the treatment of AML and soft tissue sarcoma, indicating a medically plausible basis for its use[50]. - The FDA has granted Fast Track Designation for Annamycin, allowing for expedited development and review processes[50]. - The WP1066 Portfolio Program has received FDA orphan drug designation for glioblastoma treatment, indicating a medically plausible basis for its use[111]. - The FDA granted WP1066 a "Rare Pediatric Disease" designation, which may provide a Priority Review Voucher valued at up to $100 million upon approval[186]. Company Operations and Financials - The company has a workforce of 17 employees as of year-end 2025, operating primarily in a virtual environment without manufacturing facilities[146]. - The company relies on third-party contract manufacturers for all aspects of API manufacturing and drug product formulation[149]. - Total expenses under license agreements with MD Anderson were $0.2 million and $0.3 million for the years ended December 31, 2025 and 2024, respectively[168]. - The company has a sponsored research agreement with MD Anderson running until March 31, 2027, with expenses of $2.0 million and $0.8 million for the years ended December 31, 2025 and 2024, respectively[170]. - The company has sublicensed certain intellectual property rights to Animal Life Sciences, requiring commercialization efforts for non-human uses of Annamycin by 2028[171]. - The ALI Agreement requires ALI to pay a royalty of 5.0% on net sales of sublicensed products, in addition to the royalty owed to MD Anderson[172]. Future Projections and Trends - The US is expected to see 2.0 million new cancer cases and 618,120 cancer deaths in 2025, translating to approximately 1,693 deaths per day[174]. - There are 551 ongoing clinical trials for pancreatic cancer, indicating significant competition and development activity in this area[200]. - The FDA requires extensive preclinical data and compliance with Good Laboratory Practice (GLP) before human clinical trials can begin[206]. - Clinical trials are conducted in three phases, with Phase 1 focusing on safety and dosage, Phase 2 on effectiveness, and Phase 3 on risk/benefit analysis[210]. - The NDA submission process includes substantial fees and must demonstrate safety and effectiveness across all relevant pediatric subpopulations[215]. - The FDA aims to complete NDA reviews within 12 months, but this can be extended for additional information requests[216]. - The FDA has programs to expedite drug development for serious conditions, but eligibility can change based on specific product candidate circumstances[217]. - Priority Review aims to complete NDA review within eight months of submission[219]. - Accelerated Approval allows for approval based on surrogate endpoints that predict clinical benefit[219]. - Fast Track enables rolling review of NDA sections before complete application submission[219]. - Breakthrough Therapy provides for expedited review and rolling review of NDA[219].

Financial Performance - The company reported an operating loss of $13.99 million for the year ended December 31, 2025, compared to a loss of $12.05 million in 2024, reflecting an increase in operating expenses [360]. - The accumulated deficit reached approximately $100.8 million as of December 31, 2025, with a net loss of about $13.56 million for the year [372]. - The company had no revenue for the years ended December 31, 2025 and 2024, with no immediate sales prospects [361]. Research and Development - Research and development costs increased to $7.81 million in 2025 from $7.27 million in 2024, primarily due to ongoing testing and related expenses for the Phase 1B trial for NGC-Cap [364]. - The company anticipates future increases in research and development costs as it finalizes clinical trials and expands its development team [365]. - The company anticipates ongoing negative cash flows from operating activities due to continued research and development efforts [377]. Expenses - General and administrative expenses rose to $6.18 million in 2025, up from $4.78 million in 2024, driven by increases in salaries, stock-based compensation, and professional fees [368]. - Net cash used in operating activities increased to $11,385,195 in 2025 from $11,245,042 in 2024, primarily due to higher costs related to the Phase 2 trial for NGC-Cap and increased payroll expenses [377]. - As of December 31, 2025, prepaid expenses included $1.0 million for advanced payments related to Phase 1B and Phase 2 trials of NGC-Cap [378]. Cash and Financing - Cash and cash equivalents stood at $5.5 million as of December 31, 2025, following a net cash increase of $4.35 million during the year [371]. - The company plans to raise additional capital in the second quarter of 2026 to support ongoing research and development activities [372]. - Net proceeds from financing activities in 2025 totaled approximately $10.6 million from the sale of common stock and warrants [380]. - In 2024, net proceeds from financing activities amounted to $6.3 million from the sale of common stock in a public offering [381]. - The company has filed a registration statement for an at-the-market offering of up to $50 million, with an initial offering price of up to $5.2 million [359]. Digital Assets - The company recorded $295,180 in unrealized gains on digital assets and $109,491 in interest income for the year ended December 31, 2025 [369]. - The company used $850,000 in investing activities to purchase digital assets in 2025 [379]. - Digital assets are measured at fair value, with significant volatility and liquidity considerations impacting valuation [395]. Contracts and Obligations - The company has entered into contracts with CROs and clinical supply manufacturers, which are generally cancelable and not included in contractual obligations [382]. - No off-balance sheet arrangements were reported during the periods presented [384]. Tax Considerations - The company recorded a valuation allowance for deferred tax assets, as it is more likely than not that benefits will not be realized [393].

Financial Performance - In 2025, XOMA received total cash receipts of $50.5 million, comprising $33.6 million from commercial payments and $16.9 million from milestone payments and other fees[35]. - The company generated a net income of $31.7 million and cash flows from operations of $2.9 million for the year ended December 31, 2025, but has an accumulated deficit of $1.2 billion[152]. - Company received commercial payments of $1.7 million in 2025 and $1.6 million in 2024 under the Aptevo CPPA[57]. - The company has authorized a stock repurchase program allowing for the purchase of up to $50.0 million of its common stock through January 2027[98]. - As of December 31, 2025, the company had repurchased 648,708 shares for a total of $16.1 million[99]. Portfolio and Assets - The company has a diversified portfolio with economic rights to over 120 assets, including seven commercial-stage assets and 14 late-stage therapeutic candidates[38]. - XOMA's portfolio includes assets with significant commercial sales potential, primarily in Phase 1 and 2 development stages[36]. - The company has added 22 milestone and royalty interests to its portfolio since the beginning of 2025[38]. - Company acquired rights to receive potential regulatory and commercial milestone payments of up to $342.7 million and royalties on net sales of aldoxorubicin in the low to mid-teens percentage range for orphan indications[52]. - Company acquired Pulmokine for $20.0 million, with eligibility for low to mid-single-digit royalties on commercial sales of seralutinib[70]. Revenue Streams - The commercial asset VABYSMO® generated $22.5 million in royalties for XOMA in 2025, with a royalty rate of 0.5% on future net sales[40]. - XOMA earned $7.7 million in royalties from OJEMDA in 2025, following its FDA approval in April 2024[50]. - The company is eligible for mid-single-digit royalties on sales of OJEMDA, with additional milestone payments received in 2025 totaling $15 million[49]. - Company paid $22.0 million for 100% of remaining royalties related to XACIATO, with royalties ranging from low to high single digits[58]. - The company is eligible to receive milestone payments of up to $20.8 million related to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products under the Takeda Collaboration Agreement[83]. Acquisitions and Transactions - XOMA's strategy includes acquiring additional milestone and royalty revenue streams, having closed seven transactions since the beginning of 2025, adding approximately $11.7 million in cash and cash equivalents[37]. - Company entered into the Twist RPA for $15.0 million, eligible to receive up to $0.5 billion in milestone payments and low single-digit royalties[75]. - Company acquired an economic interest in DSUVIA for $8.0 million, with potential royalties of 15% on commercial sales[60]. - The company plans to continue business development efforts to acquire potential milestone and royalty streams or companies, with future growth dependent on the availability of suitable products at acceptable prices and terms[175]. - The company may seek to expand market opportunities by acquiring securities from other biopharmaceutical companies, which could involve risks and uncertainties[124]. Risks and Challenges - The company faces competition from other firms seeking to aggregate royalties and provide financing to biotechnology companies, which may impact its market position[103]. - A significant portion of the company's portfolio value is concentrated in a limited number of products, indicating that the failure of any one product could materially impact financial results[112]. - The company may face challenges in integrating acquired assets, which could disrupt operations and dilute shareholder value[121]. - The company is dependent on third parties to achieve development milestones and product sales, which could affect financial performance[112]. - The company may not be able to realize anticipated benefits from acquisitions or in-licensing due to integration risks and unforeseen challenges[176]. Regulatory and Market Conditions - Regulatory approvals for development-stage product candidates are subject to extensive requirements, and unknown problems may lead to marketing restrictions or product withdrawals[129]. - The company’s potential royalty providers may face significant delays in clinical trials due to various factors, including patient enrollment challenges and regulatory requirements[187]. - Changes in regulatory policies under the current U.S. Presidential administration may create uncertainty for the company's licensees and their business operations[148]. - The introduction of generic drugs can significantly reduce sales of branded products, adversely affecting potential milestones and royalties[210]. - The FDA's interpretation of orphan drug exclusivity may change, affecting the competitive landscape for drugs with orphan designation[198]. Intellectual Property - The company and its potential royalty providers rely on patent protection, copyright, trade secret, and trademark laws to safeguard proprietary technology, but these protections may be limited[226]. - The validity and enforceability of issued patents are uncertain, and U.S. patents may be subject to post-grant review procedures that could result in the loss of valuable patent rights[229]. - Inadequate protection of intellectual property rights could hinder the commercialization of technologies or products, negatively impacting sales and market share[230]. - The biotechnology patent landscape is highly uncertain, with evolving legal standards that may affect the validity of patents[230]. - Competitors may design around existing patents or develop superior technologies, impacting the company's market position[233].

Financial Performance - In 2025, XOMA received total cash receipts of $50.5 million, comprising $33.6 million from commercial payments and $16.9 million from milestone payments and other fees[35]. - XOMA earned $7.7 million in royalties from OJEMDA in 2025, following its FDA approval in April 2024[50]. - The company generated a net income of $31.7 million and cash flows from operations of $2.9 million for the year ended December 31, 2025, but has an accumulated deficit of $1.2 billion[152]. - The company has historically incurred significant operating losses and negative cash flows from operations since inception, raising concerns about future profitability[152]. - The company has financed operations primarily through equity securities, debt, and collaboration payments, with future profitability dependent on successful product development and commercialization by partners[153]. Portfolio and Assets - The company has a diversified portfolio with economic rights to over 120 assets, including seven commercial-stage assets and 14 late-stage therapeutic candidates[38]. - The commercial asset VABYSMO® generated $22.5 million in royalties for XOMA in 2025, with a royalty rate of 0.5% on future net sales[40]. - The late-stage asset Ersodetug has an estimated potential milestone of $210 million, with a royalty rate of high single digit to mid-teens[41]. - Acquired rights to receive future royalties and milestone payments related to aldoxorubicin, including potential payments of up to $342.7 million and royalties in the low to mid-teens percentage range for orphan indications[52]. - The company’s asset portfolio is not fully diversified, and the failure of key products could materially affect financial results, as seen with the termination of the iscalimab license agreement[171]. Milestone and Royalty Strategy - XOMA's strategy includes acquiring additional milestone and royalty revenue streams, having closed seven transactions since the beginning of 2025, adding approximately $11.7 million in cash and cash equivalents[37]. - The company has added 22 milestone and royalty interests to its portfolio since the beginning of 2025[38]. - The company is eligible for up to $54.0 million in potential milestone payments related to OJEMDA, following an upfront payment of $13.5 million for the acquisition of rights[48]. - The company is eligible to receive milestone payments of up to $20.8 million related to TAK-079 (mezagitamab) and a 4% royalty on future sales of all products under the Takeda Collaboration Agreement[83]. - The company has earned three milestone payments totaling $12.0 million under the Rezolute License Agreement for the development of ersodetug (RZ358) as of May 2025[87]. Regulatory and Market Risks - Regulatory approvals for development-stage product candidates are subject to extensive requirements, and unknown problems may lead to restrictions or market withdrawal, negatively impacting potential royalty payments[129]. - The biopharmaceutical industry is highly competitive, and products generating royalties may become obsolete due to new developments or regulatory changes, affecting revenue[140]. - The FDA and other regulatory agencies have substantial discretion in the approval process, which can lead to delays or rejections of product applications[184]. - The company may face material impacts on royalties if royalty providers are unable to obtain or transfer Rare Pediatric Disease Priority Review Vouchers[207]. - The introduction of generic drugs could significantly reduce sales of branded products, adversely affecting potential milestones and royalties[210]. Competition and Market Position - The company faces competition from other entities seeking to aggregate royalties or provide financing to biotechnology and pharmaceutical companies, which may impact its market position[103]. - The competition for acquiring or in-licensing promising products is intense, with larger multinational pharmaceutical companies having more resources, which may lead to higher acquisition costs[175]. - There is no assurance that future asset acquisitions will yield returns or risk profiles similar to the current portfolio, and profitability is uncertain[173]. - The company may face reduced opportunities in the royalty acquisition market due to changes in competition and industry growth rates[159]. Intellectual Property and Legal Risks - The company holds a number of patents and applications in the U.S. and internationally, with expected expiration dates ranging from 2028 to 2043 for various programs[108]. - The validity and enforceability of issued patents are uncertain, and U.S. patents may be subject to post-grant review procedures that could result in the loss of valuable patent rights[229]. - Potential infringement on the intellectual property rights of others could lead to costly litigation and reduced royalties[233]. - Reliance on trade secrets and confidentiality agreements is crucial for maintaining competitive advantage, but breaches may occur[232]. Business Development and Future Growth - The company plans to continue business development efforts to acquire potential milestone and royalty streams or companies, with future growth depending on the availability of suitable products at acceptable prices and terms[175]. - The company is actively reviewing acquisition opportunities in various stages, which may involve significant competition and costs[119]. - The company may seek to expand its market opportunity by acquiring securities from other biopharmaceutical companies, which may carry risks and uncertainties[124]. - The company’s royalty aggregator strategy relies heavily on the successful development and commercialization of clinical-stage product candidates[126].

RED CAT REPORTS RECORD Q4 REVENUE GROWTH AND 161% FULL-YEAR REVENUE INCREASE YoY; INCREASED PRODUCTION CAPACITY BY 520% WITH MOMENTUM BUILDING INTO 2026 SALT LAKE CITY, UT., March 18, 2026 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) ("Red Cat" or the "Company"), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, reports its financial results for the year ended December 31, 2025. Fourth Quarter and Full-Year 2025 Financial Highlights Exhi ...

Financial Performance - In Q3 fiscal 2026, net sales decreased by 8% to $4,436.7 million, with organic net sales down 3% compared to the same period last year [108]. - Operating profit fell 41% to $525 million, with an operating profit margin of 11.8%, a decrease of 660 basis points [108]. - Diluted earnings per share decreased by 50% to $0.56, while adjusted diluted earnings per share decreased by 37% on a constant-currency basis to $0.64 [108]. - For the nine-month period ended February 22, 2026, net sales decreased by 7% to $13,815.0 million, with organic net sales down 3% [123]. - Adjusted operating profit for the nine-month period decreased by 23% on a constant-currency basis to $2,106.1 million, with an adjusted operating profit margin of 15.2% [124]. - Adjusted operating profit for the quarter ended February 22, 2026, was $547.2 million, representing a 12.3% margin, compared to $800.8 million and a 16.5% margin for the same quarter in the previous year [204]. - Adjusted diluted earnings per share for the quarter ended February 22, 2026, was $0.64, a decrease of 36% compared to $1.00 in the previous year [211]. - Adjusted diluted earnings per share for the nine-month period ended February 22, 2026, was $3.47, a decrease of 25% compared to the previous year [211]. Costs and Expenses - SG&A expenses decreased by $32 million to $813 million in Q3 fiscal 2026, but as a percentage of net sales, they increased by 90 basis points [114]. - Cost of sales decreased by $449 million to $9,223 million for the nine-month period ended February 22, 2026, primarily due to an $889 million decrease from lower volume [130]. - SG&A expenses decreased by $51 million to $2,500 million for the nine-month period ended February 22, 2026, with SG&A as a percentage of net sales increasing by 100 basis points [131]. - Unallocated corporate expenses rose to $75 million in Q3 2026 from $56 million in Q3 2025, with restructuring charges of $8 million recorded in Q3 2026 [173]. Taxation - The effective tax rate for Q3 fiscal 2026 was 24.3%, up from 19.8% in the same period last year, primarily due to nonrecurring discrete tax benefits in fiscal 2025 [118]. - The effective tax rate increased to 24.8% for the nine-month period ended February 22, 2026, compared to 20.5% in the same period last year [135]. - Adjusted effective income tax rate for the quarter ended February 22, 2026, was 24.0%, compared to 19.8% in the previous year [216]. Restructuring and Transformation - The company recorded $24 million in restructuring and transformation costs in Q3 fiscal 2026, compared to $1 million in net recoveries in the same period last year [116]. - Restructuring and transformation costs totaled $163 million for the nine-month period ended February 22, 2026, compared to $3 million in the same period last year [133]. - Restructuring and transformation charges recorded in fiscal 2026 amounted to $123.3 million, contributing to the adjusted operating profit [195]. Divestitures and Acquisitions - The company expects the net impact of divestitures and acquisitions to reduce adjusted operating profit growth by approximately 5 points in fiscal 2026 [106]. - The company recorded a $1,049 million gain from divestitures in the nine-month period ended February 22, 2026, primarily from the sale of its U.S. yogurt business [132]. - The company reported a net divestitures gain primarily related to the sale of its United States yogurt business in fiscal 2026 [193]. Segment Performance - International net sales increased by 6% to $2,185.4 million for the nine-month period ended February 22, 2026, driven by favorable foreign currency exchange impacts and volume growth [154]. - North America Retail net sales decreased by 13% to $8,105.2 million for the nine-month period ended February 22, 2026, primarily due to a decrease in contributions from volume growth [144]. - Segment operating profit for North America Retail decreased by 25% to $1,683 million for the nine-month period ended February 22, 2026, impacted by higher input costs [151]. - International segment operating profit increased by 104% to $128 million for the nine-month period ended February 22, 2026, driven by favorable net price realization and mix [158]. - North America Pet net sales increased by 3% to $640.5 million in Q3 2026 compared to Q3 2025, driven by favorable net price realization and mix [159]. - For the nine-month period ended February 22, 2026, North America Pet net sales rose by 6% to $1,910.9 million, with contributions from acquisitions accounting for 6 percentage points of growth [161]. - North America Foodservice net sales decreased by 11% to $496.4 million in Q3 2026, primarily due to a decline in volume growth and unfavorable net price realization [167]. - Segment operating profit for North America Pet increased by 1% to $103 million in Q3 2026, while it decreased by 6% to $339 million for the nine-month period [164][165]. Cash Flow and Financing - Cash provided by operations decreased by $692 million to $1,614 million for the nine-month period ended February 22, 2026, primarily due to a decrease in net earnings [175]. - Cash used by financing activities increased significantly to $2,644 million in the nine-month period ended February 22, 2026, compared to $610 million in the same period last year [177]. - As of February 22, 2026, the company had $698 million in cash and cash equivalents in foreign jurisdictions, with plans to repatriate these funds without incurring further U.S. income tax liability [178]. - The company has $2,138 million of long-term debt maturing in the next 12 months, which is classified as current [181]. - The company maintains a committed credit facility of $2,700 million expiring in October 2029, with total available credit facilities amounting to $3,476.8 million [179]. Impairment and Risks - The company recorded a non-cash impairment charge of $53 million for the Uncle Toby's brand intangible asset due to lower future sales and profitability projections [184]. - The company is monitoring the Progresso, Nudges, True Chews, and Kitano brand intangible assets for potential impairment risks [186]. - The estimated maximum potential value-at-risk for interest rate instruments was $32 million, reflecting a decrease of $14 million during the nine-month period ended February 22, 2026 [237]. - The value-at-risk for foreign currency instruments was $42 million, with a decrease of $9 million during the same period [237]. - Commodity and equity instruments both had a value-at-risk of $3 million, which is considered immaterial [237]. Future Outlook - The company plans to increase investment in consumer value, product innovation, and brand building to drive future growth [106]. - The company anticipates the new accounting standards for internal-use software to impact its financial position starting in fiscal 2029 [187]. - The company is analyzing the impact of recently issued accounting standards on its disclosures and financial results [189]. - Organic net sales growth rates are provided to exclude the effects of foreign currency fluctuations, acquisitions, and divestitures, offering transparency in underlying performance [202].

Financial Performance - Total revenue for 2025 reached $893,000, a significant increase from $76,000 in 2024[25]. - The net loss before noncontrolling interest was $151.6 million in 2025, compared to $163.3 million in 2024[11]. - Net loss available to Class A common stockholders was $68,986, compared to a loss of $61,186 in 2024[25]. - Operating expenses totaled $165,900, down from $183,752 in 2024, with R&D expenses at $114,123[25]. Cash and Assets - ProKidney ended 2025 with $270.0 million in cash and cash equivalents, down from $358.3 million in 2024, expected to fund operations into mid-2027[8]. - Cash and cash equivalents increased to $108,537 from $99,120 in 2024, reflecting a positive cash flow trend[27]. - Total assets decreased to $335,574 from $441,073 in 2024, indicating a reduction in overall asset base[23]. - Total liabilities decreased to $34,781 from $39,436 in 2024, showing improved financial health[23]. Research and Development - Research and development expenses decreased to $114.1 million in 2025 from $127.7 million in 2024, primarily due to a reduction in clinical study costs[9]. - ProKidney is on track to complete enrollment for the Phase 3 PROACT 1 study by mid-2026, with pivotal topline results anticipated in Q2 2027[6]. - Positive results from the Phase 2 REGEN-007 study were presented at ASN Kidney Week 2025, followed by a peer-reviewed publication[7]. - The FDA confirmed that eGFR slope can serve as a surrogate endpoint for the accelerated approval of rilparencel during a Type B meeting in July 2025[7]. Manufacturing and Future Plans - ProKidney initiated an expansion of its in-house manufacturing footprint, totaling 180,000 square feet in Winston-Salem, NC[7]. - The company plans to submit a Biologics License Application (BLA) for rilparencel in Q4 2027, with commercial launch expected in 2H 2028[13]. - ProKidney aims to address the unmet medical need for therapies in patients with advanced CKD and diabetes, a population exceeding 1 million in the U.S.[14]. Cash Flow - The company reported a net cash flow used in operating activities of $120,117, slightly improved from $126,351 in 2024[27]. - The company experienced a net cash flow provided by investing activities of $103,965, a significant increase from $20,414 in 2024[27]. - Proceeds from sales of Class A common stock amounted to $24,247, down from $144,322 in 2024[27]. - The weighted average shares of Class A common stock outstanding increased to 133,942,736 from 97,916,193 in 2024[25].

Financial Performance - Revenue for Q2 2026 reached $23.86 billion, a significant increase from $13.64 billion in Q1 2026 and $8.05 billion in Q2 2025[5] - GAAP net income was $13.79 billion, translating to $12.07 per diluted share, compared to $5.24 billion and $4.60 per diluted share in the previous quarter[5] - Non-GAAP net income for Q2 2026 was $14.02 billion, or $12.20 per diluted share, reflecting strong operational performance[5] - Operating cash flow increased to $11.90 billion, up from $8.41 billion in Q1 2026 and $3.94 billion in Q2 2025[5] - Net income for the six months ended February 26, 2026, was $19,025 million, a significant increase from $3,453 million in the same period of 2025[18] - Net cash provided by operating activities rose to $20,314 million in 2026, compared to $7,186 million in 2025, reflecting a strong operational performance[18] - GAAP gross margin for the second quarter of 2026 was $17,755 million, up from $7,646 million in the first quarter of 2026[20] - Non-GAAP net income for the second quarter of 2026 reached $14,021 million, compared to $5,482 million in the first quarter of 2025[20] - Adjusted free cash flow for the second quarter of 2026 was $6,899 million, significantly higher than $3,906 million in the first quarter of 2025[22] Guidance and Projections - Micron's guidance for Q3 2026 projects revenue of approximately $33.5 billion, with a gross margin of around 81%[7] - The company expects revenue for FQ3-26 to be approximately $33.5 billion, with a gross margin of approximately 81%[26] - GAAP diluted earnings per share for FQ3-26 is projected to be $18.90 ± $0.40, while non-GAAP diluted earnings per share is expected to be $19.15 ± $0.40[26] Capital Expenditures and Cash Management - Capital expenditures for Q2 2026 were $5.0 billion, with adjusted free cash flow reported at $6.9 billion[4] - The company reported expenditures for property, plant, and equipment of $11,776 million for the six months ended February 26, 2026, compared to $7,261 million in 2025[18] - Micron ended the quarter with total cash, marketable investments, and restricted cash of $16.7 billion[4] - Cash, cash equivalents, and restricted cash at the end of the period were $13,934 million, up from $7,563 million at the end of the same period in 2025[18] Dividend and Stock Repurchase - The company declared a quarterly dividend of $0.15 per share, marking a 30% increase, payable on April 15, 2026[3] - The company repurchased $650 million of common stock under its repurchase program during the six months ended February 26, 2026[18] Business Unit Performance - The Cloud Memory Business Unit generated revenue of $7.75 billion, up from $5.28 billion in Q1 2026, with a gross margin of 74%[6] - Micron's gross margin for Q2 2026 was 74.9%, compared to 56.8% in Q1 2026 and 37.9% in Q2 2025[4]